title: A live-attenuated chimeric porcine circovirus type 2 (PCV2) vaccine is transmitted to contact pigs but is not upregulated by concurrent infection with porcine parvovirus (PPV) and porcine reproductive and respiratory syndrome virus (PRRSV) and is efficacious in a PCV2b-PRRSV-PPV challenge model.
abstract: The live chimeric porcine circovirus type 2 (PCV2) vaccine with the capsid gene of the emerging subtype 2b cloned in the genomic backbone of the nonpathogenic PCV1 is attenuated in vivo and induces protective immunity against PCV2. To further determine the safety and efficacy of this experimental vaccine, we tested for evidence of pig-to-pig transmission by commingling nonvaccinated and vaccinated pigs, determined potential upregulation by simultaneous vaccination and infection with porcine parvovirus (PPV) and porcine reproductive and respiratory syndrome virus (PRRSV), and determined vaccine efficacy by challenging pigs 4 weeks after vaccination with PCV2b, PRRSV, and PPV. Forty-six 21-day-old, PCV2-naïve pigs were randomly assigned to one of six groups. Twenty-nine of 46 pigs were challenged with PCV2b, PRRSV, and PPV at day 28, 8/46 remained nonvaccinated and nonchallenged and served as negative controls, and 9/46 remained nonchallenged and served as vaccination controls. All animals were necropsied at day 49. PCV1-PCV2 viremia was detected in nonvaccinated contact pigs commingled with vaccinated pigs, indicating pig-to-pig transmission; however, PCV1-PCV2 DNA levels remained low in all vaccinated and contact pigs regardless of concurrent infection. Finally, vaccination 28 days before challenge resulted in significantly (P < 0.05) decreased amounts of PCV2 in tissues and sera and significantly (P < 0.05) reduced macroscopic and microscopic lesions. The results of this study indicate that the experimental live-attenuated chimeric PCV2 vaccine, although transmissible to contact pigs, remains attenuated in pigs concurrently infected with PRRSV and PPV and induces protective immunity against PCV2b when it is administered 28 days before PCV2 exposure.
authors.affiliation: Department of Veterinary Diagnostic and Production Animal Medicine, College of Veterinary Medicine, Iowa State University, Ames, IA 50011, USA. tanjaopr@iastate.edu
authors.forename: T
authors.initials: T
authors.lastname: Opriessnig
authors.forename: H G
authors.initials: HG
authors.lastname: Shen
authors.forename: N
authors.initials: N
authors.lastname: Pal
authors.forename: S
authors.initials: S
authors.lastname: Ramamoorthy
authors.forename: Y W
authors.initials: YW
authors.lastname: Huang
authors.forename: K M
authors.initials: KM
authors.lastname: Lager
authors.forename: N M
authors.initials: NM
authors.lastname: Beach
authors.forename: P G
authors.initials: PG
authors.lastname: Halbur
authors.forename: X J
authors.initials: XJ
authors.lastname: Meng
mesh_terms: D000818:Animals; D018173:Circoviridae Infections / Q000276:immunology / Q000517:prevention & control / Q000662:veterinary* / Q000821:virology; D017925:Circovirus / Q000276:immunology*; D028323:Parvovirus, Porcine / Q000276:immunology; D019316:Porcine respiratory and reproductive syndrome virus / Q000276:immunology; D013552:Swine; D013553:Swine Diseases / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology; D014765:Viral Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*
chemical_list: D014613:Vaccines, Attenuated; D014765:Viral Vaccines